BioNTech (NASDAQ:BNTX) PT Raised to $113.00 at HC Wainwright

BioNTech (NASDAQ:BNTX) had its price objective hoisted by HC Wainwright from $107.00 to $113.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

Several other analysts have also recently weighed in on BNTX. UBS Group dropped their price objective on BioNTech from $110.00 to $101.00 and set a neutral rating for the company in a report on Wednesday, March 27th. BMO Capital Markets dropped their price target on shares of BioNTech from $123.00 to $122.00 and set an outperform rating for the company in a research note on Tuesday. TD Cowen raised their price objective on shares of BioNTech from $95.00 to $98.00 and gave the company a hold rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a research report on Friday, March 22nd. Finally, Canaccord Genuity Group reissued a buy rating and issued a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of Hold and a consensus target price of $118.82.

BioNTech Trading Down 0.8 %

Shares of NASDAQ BNTX opened at $90.13 on Wednesday. BioNTech has a 1-year low of $85.21 and a 1-year high of $125.83. The company has a 50-day moving average of $90.47 and a two-hundred day moving average of $95.95. The company has a market cap of $21.43 billion, a PE ratio of 21.88 and a beta of 0.25. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. As a group, equities analysts expect that BioNTech will post -1.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently modified their holdings of BNTX. CWM LLC raised its holdings in BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after buying an additional 217 shares during the period. GAMMA Investing LLC raised its holdings in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares during the period. Frazier Financial Advisors LLC bought a new stake in BioNTech in the 4th quarter valued at $30,000. Covestor Ltd acquired a new position in BioNTech in the 3rd quarter worth $32,000. Finally, First Horizon Advisors Inc. acquired a new position in BioNTech in the 4th quarter worth $38,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.